CD8A and ovarian carcinoma: CD8 immunohistochemistry (IHC) with a haematoxylin counterstaining was performed on 370 archival tissues (treatment-naive specimen) from a subset of patients with ovarian cancer enrolled in the ICON7 trial14,15.